Dianthus Therapeutics, Inc. (DNTH)
NASDAQ · Healthcare
$101.00-4.36%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $4.18B
- P/E ratio
- —
- EPS
- —
- Volume
- 825,115
- 52-week high
- —
- 52-week low
- —
- Open
- $105.15
- Day high
- $107.99
- Day low
- $100.04
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $2.04M | -$162.34M | -$4.20 |
| 2024 | $6.24M | -$84.97M | -$2.55 |
| 2023 | $2.83M | -$43.56M | -$8.45 |
| 2022 | — | -$28.48M | -$32.57 |
| 2021 | — | -$71.14M | -$1.29 |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- CEO
- Marino Garcia
- Employees
- 92
- Country
- US
- IPO date
- Jun 21, 2018
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Dianthus Therapeutics, Inc.'s stock price today?
- DNTH is trading at $101.00 as of Jul 20, 2026.
- What is Dianthus Therapeutics, Inc.'s market cap?
- Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $4.18B.
- Does Dianthus Therapeutics, Inc. pay a dividend?
- Dianthus Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Dianthus Therapeutics, Inc. in?
- Dianthus Therapeutics, Inc. operates in the Healthcare sector.